Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.010
+0.010 (0.25%)
Mar 31, 2025, 4:00 PM EDT - Market closed
Cytek Biosciences Revenue
In the year 2024, Cytek Biosciences had annual revenue of $200.45M with 3.85% growth. Cytek Biosciences had revenue of $57.48M in the quarter ending December 31, 2024, a decrease of -1.30%.
Revenue (ttm)
$200.45M
Revenue Growth
+3.85%
P/S Ratio
2.61
Revenue / Employee
$309,341
Employees
648
Market Cap
513.67M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 200.45M | 7.44M | 3.85% |
Dec 31, 2023 | 193.02M | 28.98M | 17.67% |
Dec 31, 2022 | 164.04M | 36.09M | 28.20% |
Dec 31, 2021 | 127.95M | 35.11M | 37.82% |
Dec 31, 2020 | 92.84M | 34.96M | 60.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2011 | Pro | Pro | Pro |
Dec 31, 2010 | Pro | Pro | Pro |
Dec 31, 2009 | Pro | Pro | Pro |
Dec 31, 2007 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CTKB News
- 13 days ago - Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System - GlobeNewsWire
- 4 weeks ago - Cytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call Transcript - Seeking Alpha
- 4 weeks ago - Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook - GlobeNewsWire
- 6 weeks ago - Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - GlobeNewsWire
- 7 weeks ago - Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Upgrading Cytek Biosciences Stock On An Upcoming Catalyst - Seeking Alpha
- 3 months ago - Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025 - GlobeNewsWire